Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

689 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-dose interleukin2 - a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome.
Chow S, Galvis V, Pillai M, Leach R, Keene E, Spencer-Shaw A, Shablak A, Shanks J, Liptrot T, Thistlethwaite F, Hawkins RE. Chow S, et al. Among authors: pillai m. J Immunother Cancer. 2016 Oct 18;4:67. doi: 10.1186/s40425-016-0174-5. eCollection 2016. J Immunother Cancer. 2016. PMID: 27777776 Free PMC article.
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
Thistlethwaite FC, Gilham DE, Guest RD, Rothwell DG, Pillai M, Burt DJ, Byatte AJ, Kirillova N, Valle JW, Sharma SK, Chester KA, Westwood NB, Halford SER, Nabarro S, Wan S, Austin E, Hawkins RE. Thistlethwaite FC, et al. Among authors: pillai m. Cancer Immunol Immunother. 2017 Nov;66(11):1425-1436. doi: 10.1007/s00262-017-2034-7. Epub 2017 Jun 28. Cancer Immunol Immunother. 2017. PMID: 28660319 Free PMC article. Clinical Trial.
Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma.
Pillai M, Jiang Y, Lorigan PC, Thistlethwaite FC, Thomas M, Kirillova N, Bridgeman JS, Kueberuwa G, Biswas S, Velazquez P, Chonzi D, Guest RD, Roberts ZJ, Hawkins RE. Pillai M, et al. Am J Cancer Res. 2022 Aug 15;12(8):3967-3984. eCollection 2022. Am J Cancer Res. 2022. PMID: 36119832 Free PMC article.
Immune biomarker evaluation of sequential tyrosine kinase inhibitor and nivolumab monotherapies in renal cell carcinoma: the phase I TRIBE trial.
Shohdy KS, Pillai M, Abbas KS, Allison J, Waddell T, Darlington E, Mohammad S, Hood S, Atkinson S, Simpson K, Morgan D, Nathan P, Kilgour E, Dive C, Thistlethwaite F. Shohdy KS, et al. Among authors: pillai m. Immunooncol Technol. 2024 Mar 18;22:100712. doi: 10.1016/j.iotech.2024.100712. eCollection 2024 Jun. Immunooncol Technol. 2024. PMID: 38694705 Free PMC article.
Acute and Chronic Cardiopulmonary Effects of High Dose Interleukin-2 Therapy: An Observational Magnetic Resonance Imaging Study.
Lagan J, Naish JH, Fortune C, Campbell C, Chow S, Pillai M, Bradley J, Francis L, Clark D, Macnab A, Nucifora G, Dobson R, Schelbert EB, Schmitt M, Hawkins R, Miller CA. Lagan J, et al. Among authors: pillai m. Diagnostics (Basel). 2022 May 30;12(6):1352. doi: 10.3390/diagnostics12061352. Diagnostics (Basel). 2022. PMID: 35741162 Free PMC article.
689 results